Collaboration and License Agreements (Tables)

9 Months Ended

Dec. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

Collaboration and License Agreements

The following table presents changes in the Company’s contract liabilities during the nine months ended December 31, 2022 (in thousands):

	Balance at March 31, 2022		Additions		Imputed Interest		Deductions		Balance at December 31, 2022
Contract liabilities:
Deferred revenue (1)	$	476,270	$	100,000	$	—	$	(109,025)	$	467,245
Cost share advance from Pfizer (2)	$	33,818	$	—	$	568	$	(34,386)	$	—

(1) Includes $117.2 million and $350.0 million presented as current and non-current, respectively, on the unaudited condensed consolidated balance sheet as of December 31, 2022. Includes $100.6 million and $375.7 million presented as current and non-current, respectively, on the unaudited condensed consolidated balance sheet as of March 31, 2022.

(2) Includes $33.8 million presented as current on the unaudited condensed consolidated balance sheet as of March 31, 2022.